Spotlight On Non-Small Cell Lung Cancer
Up to 85 percent of all lung cancer cases are characterized as non-small cell lung cancer, underscoring the importance of keeping up to date on the latest diagnostic and treatment advances. That’s why this Spotlight on Non-Small Cell Lung Cancer brings together leading oncologists and other allied healthcare professionals to discuss key research updates and other novel insights.
1-15 of 26
Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Project Oncology®Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Raghava Reddy Induru, MD
Choosing the Right Treatment in ALK and ROS1-Positive NSCLC
Project Oncology®Choosing the Right Treatment in ALK and ROS1-Positive NSCLC
Raghava Reddy Induru, MD
Jobelle Baldonado, MD
Oncogenic Drivers in Never-Smokers with NSCLC
Project Oncology®Oncogenic Drivers in Never-Smokers with NSCLC
Apar Kishor Ganti, MD, MS
Expanding Molecular Testing in Community NSCLC Care
Project Oncology®Expanding Molecular Testing in Community NSCLC Care
Apar Kishor Ganti, MD, MS
- advertisement
Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
Project Oncology®Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
Understanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
AudioAbstractsUnderstanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
Ryan Quigley
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Project Oncology®Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
- advertisement
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Project Oncology®AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Project Oncology®Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
